US drug regulator classifies Aurobindo Pharma arm's Andhra facility as 'voluntary action indicated'
Aurobindo Pharma Limited has announced that its subsidiary, Apitoria Pharma Pvt Ltd, received a VAI classification for its facility. The classification indicates that some objectionable conditions were found, but no regulatory actions will occur. ...
A 'VAI' classification means that while objectionable conditions or practices were found during the inspection, the agency is not prepared to take or recommend any administrative or regulatory action.
The United States Food and Drug Administration (USFDA) had inspected Unit-VI of Apitoria Pharma, at Anakapalli district, Andhra Pradesh, from August 24-28, 2026, and concluded with three observations, Aurobindo Pharma said in a regulatory filing.
The unit has now received the Establishment Inspection Report (EIR), classifying the facility as VAI, the company said, adding, "The USFDA has concluded that this inspection is now closed."
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.